|
1
|
Fan ST, Lo Mau C, Poon RT, Yeung C, Liu
Leung C, Yuen WK, Ming LC, Ng KK and Chan Ching S: Continuous
improvement of survival outcomes of resection of hepatocellular
carcinoma: A 20-year experience. Ann Surg. 253:745–758. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bruix J and Sherman M: American
Association for the Study of Liver Diseases: Management of
hepatocellular carcinoma: An update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Woerns MA and Galle PR: Future
perspectives in hepatocellular carcinoma. Digest Liver Dis. 42
Suppl 3:S302–S309. 2010. View Article : Google Scholar
|
|
4
|
Rountree CB, Mishra L and Willenbring H:
Stem cells in liver diseases and cancer: Recent advances on the
path to new therapies. Hepatology. 55:298–306. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ji J and Wang XW: Clinical implications of
cancer stem cell biology in hepatocellular carcinoma. Semin Oncol.
39:461–472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Skubitz AP, Taras EP, Boylan KL, Waldron
NN, Oh S, Panoskaltsis-Mortari A and Vallera DA: Targeting CD133 in
an in vivo ovarian cancer model reduces ovarian cancer progression.
Gynecol Oncol. 130:579–587. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen J, Liu Q, Xiao J and Du J:
EpCAM-antibody-labeled noncytotoxic polymer vesicles for cancer
stem cells-targeted delivery of anticancer drug and siRNA.
Biomacromolecules. 16:1695–1705. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lawson DA, Bhakta NR, Kessenbrock K,
Prummel KD, Yu Y, Takai K, Zhou A, Eyob H, Balakrishnan S, Wang CY,
et al: Single-cell analysis reveals a stem-cell program in human
metastatic breast cancer cells. Nature. 526:131–135. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang Y, Fan Y, Qi Y, Liu D, Wu K, Wen F
and Zhao S: Side population cells separated from A549 lung cancer
cell line possess cancer stem cell-like properties and inhibition
of autophagy potentiates the cytotoxic effect of cisplatin. Oncol
Rep. 34:929–935. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Iacopino F, Angelucci C, Piacentini R,
Biamonte F, Mangiola A, Maira G, Grassi C and Sica G: Isolation of
cancer stem cells from three human glioblastoma cell lines:
Characterization of two selected clones. Plos One. 9:e1051662014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Steiner JW, Perz ZM and Taichman LB: Cell
population dynamics in the liver. A review of quantitative
morphological techniques applied to the study of physiological and
pathological growth. Exp Mol Pathol. 5:146–181. 1966. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Turner R, Lozoya O, Wang Y, Cardinale V,
Gaudio E, Alpini G, Mendel G, Wauthier E, Barbier C, Alvaro D and
Reid LM: Human hepatic stem cell and maturational liver lineage
biology. Hepatology. 53:1035–1045. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang X, Foster M, Al-Dhalimy M, Lagasse E,
Finegold M and Grompe M: The origin and liver repopulating capacity
of murine oval cells. Proc Natl Acad Sci USA. 100 Suppl
1:S11881–S11888. 2003. View Article : Google Scholar
|
|
14
|
Libbrecht L, De Vos R, Cassiman D, Desmet
V, Aerts R and Roskams T: Hepatic progenitor cells in
hepatocellular adenomas. Am J Surg Pathol. 25:1388–1396. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Crosby HA, Hubscher SG, Joplin RE, Kelly
DA and Strain AJ: Immunolocalization of OV-6, a putative progenitor
cell marker in human fetal and diseased pediatric liver.
Hepatology. 28:980–985. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang W, Yan HX, Chen L, Liu Q, He YQ, Yu
LX, Zhang SH, Huang DD, Tang L, Kong XN, et al: Wnt/beta-catenin
signaling contributes to activation of normal and tumorigenic liver
progenitor cells. Cancer Res. 68:4287–4295. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang W, Wang C, Lin Y, Liu Q, Yu LX, Tang
L, Yan HX, Fu J, Chen Y, Zhang HL, et al: OV6+
tumor-initiating cells contribute to tumor progression and invasion
in human hepatocellular carcinoma. J Hepatol. 57:613–620. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Navarro-Alvarez N, Soto-Gutierrez A and
Kobayashi N: Hepatic stem cells and liver development. Methods Mol
Biol. 640:181–236. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Clarke MF, Dick JE, Dirks PB, Eaves CJ,
Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer
stem cells-perspectives on current status and future directions:
AACR Workshop on cancer stem cells. Cancer Res. 66:9339–9344. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chiba T, Kita K, Zheng YW, Yokosuka O,
Saisho H, Iwama A, Nakauchi H and Taniguchi H: Side population
purified from hepatocellular carcinoma cells harbors cancer stem
cell-like properties. Hepatology. 44:240–251. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu LL, Fu D, Ma Y and Shen XZ: The power
and the promise of liver cancer stem cell markers. Stem Cells Dev.
20:2023–2030. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gournay J, Auvigne I, Pichard V, Ligeza C,
Bralet MP and Ferry N: In vivo cell lineage analysis during
chemical hepatocarcinogenesis in rats using retroviral-mediated
gene transfer: Evidence for dedifferentiation of mature
hepatocytes. Lab Invest. 82:781–788. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sell S: Heterogeneity and plasticity of
hepatocyte lineage cells. Hepatology. 33:738–750. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dumble ML, Croager EJ, Yeoh GC and Quail
EA: Generation and characterization of p53 null transformed hepatic
progenitor cells: Oval cells give rise to hepatocellular carcinoma.
Carcinogenesis. 23:435–445. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Michalopoulos GK and DeFrances MC: Liver
regeneration. Science. 276:60–66. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shafritz DA, Oertel M, Menthena A,
Nierhoff D and Dabeva MD: Liver stem cells and prospects for liver
reconstitution by transplanted cells. Hepatology. 43:S89–S98. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yao Z and Mishra L: Cancer stem cells and
hepatocellular carcinoma. Cancer Biol Ther. 8:1691–1698. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Durnez A, Verslype C, Nevens F, Fevery J,
Aerts R, Pirenne J, Lesaffre E, Libbrecht L, Desmet V and Roskams
T: The clinicopathological and prognostic relevance of cytokeratin
7 and 19 expression in hepatocellular carcinoma. A possible
progenitor cell origin. Histopathology. 49:138–151. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yeh CT, Kuo CJ, Lai MW, Chen TC, Lin CY,
Yeh TS and Lee WC: CD133-positive hepatocellular carcinoma in an
area endemic for hepatitis B virus infection. BMC Cancer.
9:3242009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Okumoto K, Saito T, Haga H, Hattori E,
Ishii R, Karasawa T, Suzuki A, Misawa K, Sanjo M, Ito JI, et al:
Characteristics of rat bone marrow cells differentiated into a
liver cell lineage and dynamics of the transplanted cells in the
injured liver. J Gastroenterol. 41:62–69. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Haraguchi N, Utsunomiya T, Inoue H, Tanaka
F, Mimori K, Barnard GF and Mori M: Characterization of a side
population of cancer cells from human gastrointestinal system. Stem
Cells. 24:506–513. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jordan CT, Guzman ML and Noble M: Cancer
stem cells. N Engl J Med. 355:1253–1261. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Maugeri-Saccà M, Vigneri P and De Maria R:
Cancer stem cells and chemosensitivity. Clin Cancer Res.
17:4942–4947. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hu C, Li H, Li J, Zhu Z, Yin S, Hao X, Yao
M, Zheng S and Gu J: Analysis of ABCG2 expression and side
population identifies intrinsic drug efflux in the HCC cell line
MHCC-97L and its modulation by Akt signaling. Carcinogenesis.
29:2289–2297. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ma S, Chan KW, Lee TK, Tang KH, Wo JY,
Zheng BJ and Guan XY: Aldehyde dehydrogenase discriminates the
CD133 liver cancer stem cell populations. Mol Cancer Res.
6:1146–1153. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J and
Li J: Cancer stem/progenitor cells are highly enriched in
CD133+CD44+ population in hepatocellular
carcinoma. Int J Cancer. 126:2067–2078. 2010.PubMed/NCBI
|
|
37
|
Ma S, Lee TK, Zheng BJ, Chan KW and Guan
XY: CD133+ HCC cancer stem cells confer chemoresistance
by preferential expression of the Akt/PKB survival pathway.
Oncogene. 27:1749–1758. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Piao LS, Hur W, Kim TK, Hong SW, Kim SW,
Choi JE, Sung PS, Song MJ, Lee BC, Hwang D and Yoon SK:
CD133+ liver cancer stem cells modulate radioresistance
in human hepatocellular carcinoma. Cancer Lett. 315:129–137. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xin HW, Ambe CM, Hari DM, Wiegand GW,
Miller TC, Chen JQ, Anderson AJ, Ray S, Mullinax JE, Koizumi T, et
al: Label-retaining liver cancer cells are relatively resistant to
sorafenib. Gut. 62:1777–1786. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Haraguchi N, Ishii H, Mimori K, Tanaka F,
Ohkuma M, Kim HM, Akita H, Takiuchi D, Hatano H, Nagano H, et al:
CD13 is a therapeutic target in human liver cancer stem cells. J
Clin Invest. 120:3326–3339. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ma S, Tang KH, Chan YP, Lee TK, Kwan PS,
Castilho A, Ng I, Man K, Wong N, To KF, et al: miR-130b promotes
CD133(+) liver tumor-initiating cell growth and self-renewal via
tumor protein 53-induced nuclear protein 1. Cell Stem Cell.
7:694–707. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang J, Luo N, Luo Y, Peng Z, Zhang T and
Li S: MicroRNA-150 inhibits human CD133-positive liver cancer stem
cells through negative regulation of the transcription factor
c-Myb. Int J Oncol. 40:747–756. 2012.PubMed/NCBI
|
|
43
|
Fan ST, Yang ZF, Ho DW, Ng MN, Yu WC and
Wong J: Prediction of posthepatectomy recurrence of hepatocellular
carcinoma by circulating cancer stem cells: A prospective study.
Ann Surg. 254:569–576. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Philip PA, Mooney M, Jaffe D, Eckhardt G,
Moore M, Meropol N, Emens L, O'Reilly E, Korc M, Ellis L, et al:
Consensus report of the national cancer institute clinical trials
planning meeting on pancreas cancer treatment. J Clin Oncol.
27:5660–5669. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Park CY, Tseng D and Weissman IL: Cancer
stem cell-directed therapies: Recent data from the laboratory and
clinic. Mol Ther. 17:219–230. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yamashita T, Honda M, Nakamoto Y, Baba M,
Nio K, Hara Y, Zeng SS, Hayashi T, Kondo M, Takatori H, et al:
Discrete nature of EpCAM+ and CD90+ cancer
stem cells in human hepatocellular carcinoma. Hepatology.
57:1484–1497. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO,
Zheng BJ and Guan XY: Identification and characterization of
tumorigenic liver cancer stem/progenitor cells. Gastroenterology.
132:2542–2556. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai
P, Chu PW, Lam CT, Poon RT and Fan ST: Significance of
CD90+ cancer stem cells in human liver cancer. Cancer
Cell. 13:153–166. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Mima K, Okabe H, Ishimoto T, Hayashi H,
Nakagawa S, Kuroki H, Watanabe M, Beppu T, Tamada M, Nagano O, et
al: CD44s regulates the TGF-β-mediated mesenchymal phenotype and is
associated with poor prognosis in patients with hepatocellular
carcinoma. Cancer Res. 72:3414–3423. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wilson GS, Hu Z, Duan W, Tian A, Wang XM,
McLeod D, Lam V, George J and Qiao L: Efficacy of using cancer stem
cell markers in isolating and characterizing liver cancer stem
cells. Stem Cells Dev. 22:2655–2664. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Singh SK, Clarke ID, Terasaki M, Bonn VE,
Hawkins C, Squire J and Dirks PB: Identification of a cancer stem
cell in human brain tumors. Cancer Res. 63:5821–5828.
2003.PubMed/NCBI
|
|
52
|
Bonnet D and Dick JE: Human acute myeloid
leukemia is organized as a hierarchy that originates from a
primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Fang D, Nguyen TK, Leishear K, Finko R,
Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE and Herlyn M: A
tumorigenic subpopulation with stem cell properties in melanomas.
Cancer Res. 65:9328–9337. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Suetsugu A, Nagaki M, Aoki H, Motohashi T,
Kunisada T and Moriwaki H: Characterization of CD133+
hepatocellular carcinoma cells as cancer stem/progenitor cells.
Biochem Biophys Res Commun. 351:820–824. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Tchoghandjian A, Baeza N, Colin C, Cayre
M, Metellus P, Beclin C, Ouafik L and Figarella-Branger D: A2B5
cells from human glioblastoma have cancer stem cell properties.
Brain Pathol. 20:211–221. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Miraglia S, Godfrey W, Yin AH, Atkins K,
Warnke R, Holden JT, Bray RA, Waller EK and Buck DW: A novel
five-transmembrane hematopoietic stem cell antigen: Isolation,
characterization and molecular cloning. Blood. 90:5013–5021.
1997.PubMed/NCBI
|
|
57
|
Shmelkov SV, Jun L, St Clair R, McGarrigle
D, Derderian CA, Usenko JK, Costa C, Zhang F, Guo X and Rafii S:
Alternative promoters regulate transcription of the gene that
encodes stem cell surface protein AC133. Blood. 103:2055–2061.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Cioffi M, D'Alterio C, Camerlingo R,
Tirino V, Consales C, Riccio A, Ieranó C, Cecere SC, Losito NS,
Greggi S, et al: Identification of a distinct population of
CD133(+)CXCR4(+) cancer stem cells in ovarian cancer. Sci Rep.
5:103572015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Swaminathan SK, Roger E, Toti U, Niu L,
Ohlfest JR and Panyam J: CD133-targeted paclitaxel delivery
inhibits local tumor recurrence in a mouse model of breast cancer.
J Control Release. 171:280–287. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Rountree CB, Ding W, He L and Stiles B:
Expansion of CD133-expressing liver cancer stem cells in
liver-specific phosphatase and tensin homolog deleted on chromosome
10-deleted mice. Stem Cells. 27:290–299. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Yin S, Li J, Hu C, Chen X, Yao M, Yan M,
Jiang G, Ge C, Xie H, Wan D, et al: CD133 positive hepatocellular
carcinoma cells possess high capacity for tumorigenicity. Int J
Cancer. 120:1444–1450. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Kohga K, Tatsumi T, Takehara T, Tsunematsu
H, Shimizu S, Yamamoto M, Sasakawa A, Miyagi T and Hayashi N:
Expression of CD133 confers malignant potential by regulating
metalloproteinases in human hepatocellular carcinoma. J Hepatol.
52:872–879. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Yao J, Zhang T, Ren J, Yu M and Wu G:
Effect of CD133/prominin-1 antisense oligodeoxynucleotide on in
vitro growth characteristics of Huh-7 human hepatocarcinoma cells
and U251 human glioma cells. Oncol Rep. 22:781–787. 2009.PubMed/NCBI
|
|
64
|
Song W, Li H, Tao K, Li R, Song Z, Zhao Q,
Zhang F and Dou K: Expression and clinical significance of the stem
cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract.
62:1212–1218. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Salnikov AV, Kusumawidjaja G, Rausch V,
Bruns H, Gross W, Khamidjanov A, Ryschich E, Gebhard MM,
Moldenhauer G, Büchler MW, et al: Cancer stem cell marker
expression in hepatocellular carcinoma and liver metastases is not
sufficient as single prognostic parameter. Cancer Lett.
275:185–193. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Li J, Chen JN, Zeng TT, He F, Chen SP, Ma
S, Bi J, Zhu XF and Guan XY: CD133+ liver cancer stem
cells resist interferon-gamma-induced autophagy. BMC Cancer.
16:152016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Prasad S, Gaedicke S, Machein M, Mittler
G, Braun F, Hettich M, Firat E, Klingner K, Schuler J, Wider D, et
al: Effective eradication of glioblastoma stem cells by local
application of an AC133/CD133-specific T-cell-engaging antibody and
CD8 T cells. Cancer Res. 75:2166–2176. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Smith LM, Nesterova A, Ryan MC, Duniho S,
Jonas M, Anderson M, Zabinski RF, Sutherland MK, Gerber HP, Van
Orden KL, et al: CD133/prominin-1 is a potential therapeutic target
for antibody-drug conjugates in hepatocellular and gastric cancers.
Br J Cancer. 99:100–109. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Lang J, Lan X, Liu Y, Jin X, Wu T, Sun X,
Wen Q and An R: Targeting cancer stem cells with an 131I-labeled
anti-AC133 monoclonal antibody in human colorectal cancer
xenografts. Nucl Med Biol. 42:505–512. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Sun J, Zhang C, Liu G, Liu H, Zhou C, Lu
Y, Zhou C, Yuan L and Li X: A novel mouse CD133 binding-peptide
screened by phage display inhibits cancer cell motility in vitro.
Clin Exp Metastasis. 29:185–196. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Wang J and Zhang Q: Targeting glioblastoma
cancer stem cell marker CD133 by heptapeptide-modified DSPE-PEG
micelles. J Chin Pharm Sci. 24:2015. View Article : Google Scholar
|
|
72
|
Ashmun RA and Look AT: Metalloprotease
activity of CD13/aminopeptidase N on the surface of human myeloid
cells. Blood. 75:462–469. 1990.PubMed/NCBI
|
|
73
|
Look AT, Ashmun RA, Shapiro LH and Peiper
SC: Human myeloid plasma membrane glycoprotein CD13 (gp150) is
identical to aminopeptidase N. J Clin Invest. 83:1299–1307. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Bralet MP, Pichard V and Ferry N:
Demonstration of direct lineage between hepatocytes and
hepatocellular carcinoma in diethylnitrosamine-treated rats.
Hepatology. 36:623–630. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Guzman-Rojas L, Rangel R, Salameh A,
Edwards JK, Dondossola E, Kim YG, Saghatelian A, Giordano RJ,
Kolonin MG, Staquicini FI, et al: Cooperative effects of
aminopeptidase N (CD13) expressed by nonmalignant and cancer cells
within the tumor microenvironment. Proc Natl Acad Sci USA.
109:1637–1642. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Munoz R, Man S, Shaked Y, Lee CR, Wong J,
Francia G and Kerbel RS: Highly efficacious nontoxic preclinical
treatment for advanced metastatic breast cancer using combination
oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res.
66:3386–3391. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Christ B, Stock P and Dollinger MM: CD13:
Waving the flag for a novel cancer stem cell target. Hepatology.
53:1388–1390. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Reif AE and Allen JM: The AKR thymic
antigen and its distribution in leukemias and nervous tissues. J
Exp Med. 120:413–433. 1964. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Schlesinger M and Yron I: Antigenic
changes in lymph-node cells after administration of antiserum to
thymus cells. Science. 164:1412–1413. 1969. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Ades EW, Zwerner RK, Acton RT and Balch
CM: Isolation and partial characterization of the human homologue
of Thy-1. J Exp Med. 151:400–406. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Lu JW, Chang JG, Yeh KT, Chen RM, Tsai JJ
and Hu RM: Overexpression of Thy1/CD90 in human hepatocellular
carcinoma is associated with HBV infection and poor prognosis. Acta
Histochem. 113:833–838. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Yang ZF, Ngai P, Ho DW, Yu WC, Ng MN, Lau
CK, Li ML, Tam KH, Lam CT, Poon RT and Fan ST: Identification of
local and circulating cancer stem cells in human liver cancer.
Hepatology. 47:919–928. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Chen WC, Chang YS, Hsu HP, Yen MC, Huang
HL, Cho CY, Wang CY, Weng TY, Lai PT, Chen CS, et al: Therapeutics
targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer.
Oncotarget. 6:42923–42937. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Noto Z, Yoshida T, Okabe M, Koike C, Fathy
M, Tsuno H, Tomihara K, Arai N, Noguchi M and Nikaido T: CD44 and
SSEA-4 positive cells in an oral cancer cell line HSC-4 possess
cancer stem-like cell characteristics. Oral Oncol. 49:787–795.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Pesarrodona M, Ferrer-Miralles N, Unzueta
U, Gener P, Tatkiewicz W, Abasolo I, Ratera I, Veciana J, Schwartz
S Jr, Villaverde A and Vazquez E: Intracellular targeting of
CD44+ cells with self-assembling, protein only
nanoparticles. Int J Pharm. 473:286–295. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Kimura O, Takahashi T, Ishii N, Inoue Y,
Ueno Y, Kogure T, Fukushima K, Shiina M, Yamagiwa Y, Kondo Y, et
al: Characterization of the epithelial cell adhesion molecule
(EpCAM)+ cell population in hepatocellular carcinoma
cell lines. Cancer Sci. 101:2145–2155. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Zhang S, Wu CC, Fecteau JF, Cui B, Chen L,
Zhang L, Wu R, Rassenti L, Lao F, Weigand S and Kipps TJ: Targeting
chronic lymphocytic leukemia cells with a humanized monoclonal
antibody specific for CD44. Proc Natl Acad Sci USA. 110:6127–6132.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Cho JH, Lee SC, Ha NR, Lee SJ and Yoon MY:
A novel peptide-based recognition probe for the sensitive detection
of CD44 on breast cancer stem cells. Mol Cell Probes. 29:492–499.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Park HY, Lee KJ, Lee SJ and Yoon MY:
Screening of peptides bound to breast cancer stem cell specific
surface marker CD44 by phage display. Mol Biotechnol. 51:212–220.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Munz M, Baeuerle PA and Gires O: The
emerging role of EpCAM in cancer and stem cell signaling. Cancer
Res. 69:5627–5629. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Yamashita T, Ji J, Budhu A, Forgues M,
Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, et al:
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating
cells with stem/progenitor cell features. Gastroenterology.
136:1012–1024. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
Biffoni M, Todaro M, Peschle C and De Maria R: Identification and
expansion of human colon-cancer-initiating cells. Nature.
445:111–115. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Li C, Heidt DG, Dalerba P, Burant CF,
Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM: Identification
of pancreatic cancer stem cells. Cancer Res. 67:1030–1037. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Schmelzer E and Reid LM: EpCAM expression
in normal, non-pathological tissues. Front Biosci. 13:3096–3100.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Terris B, Cavard C and Perret C: EpCAM, a
new marker for cancer stem cells in hepatocellular carcinoma. J
Hepatol. 52:280–281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Cioffi M, Dorado J, Baeuerle PA and
Heeschen C: EpCAM/CD3-bispecific T-cell engaging antibody MT110
eliminates primary human pancreatic cancer stem cells. Clin Cancer
Res. 18:465–474. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Alibolandi M, Ramezani M, Sadeghi F,
Abnous K and Hadizadeh F: Epithelial cell adhesion molecule aptamer
conjugated PEG-PLGA nanopolymersomes for targeted delivery of
doxorubicin to human breast adenocarcinoma cell line in vitro. Int
J Pharm. 479:241–251. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Yamashita T, Forgues M, Wang W, Kim JW, Ye
Q, Jia H, Budhu A, Zanetti KA, Chen Y, Qin LX, et al: EpCAM and
alpha-fetoprotein expression defines novel prognostic subtypes of
hepatocellular carcinoma. Cancer Res. 68:1451–1461. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Gires O and Bauerle PA: EpCAM as a target
in cancer therapy. J Clin Oncol. 28:e239–e242. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Kurtz JE and Dufour P: Adecatumumab: An
anti-EpCAM monoclonal antibody, from the bench to the bedside.
Expert Opin Biol Ther. 10:951–958. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Bae JS, Noh SJ, Jang KY, Park HS, Chung
MJ, Park CK and Moon WS: Expression and role of epithelial cell
adhesion molecule in dysplastic nodule and hepatocellular
carcinoma. Int J Oncol. 41:2150–2158. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Tanimizu N, Nishikawa M, Saito H,
Tsujimura T and Miyajima A: Isolation of hepatoblasts based on the
expression of Dlk/Pref-1. J Cell Sci. 116:1775–1786. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Sununliganon L and Singhatanadgit W:
Highly osteogenic PDL stem cell clones specifically express
elevated levels of ICAM1, ITGB1 and TERT. Cytotechnology. 64:53–63.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Assis AC, Carvalho JL, Jacoby BA, Ferreira
RL, Castanheira P, Diniz SO, Cardoso VN, Goes AM and Ferreira AJ:
Time-dependent migration of systemically delivered bone marrow
mesenchymal stem cells to the infarcted heart. Cell Transplant.
19:219–230. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
De Francesco F, Tirino V, Desiderio V,
Ferraro G, D'Andrea F, Giuliano M, Libondi G, Pirozzi G, De Rosa A
and Papaccio G: Human CD34/CD90 ASCs are capable of growing as
sphere clusters, producing high levels of VEGF and forming
capillaries. PLoS One. 4:e65372009. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Brooke G, Tong H, Levesque JP and Atkinson
K: Molecular trafficking mechanisms of multipotent mesenchymal stem
cells derived from human bone marrow and placenta. Stem Cells Dev.
17:929–940. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Liu S, Li N, Yu X, Xiao X, Cheng K, Hu J,
Wang J, Zhang D, Cheng S and Liu S: Expression of intercellular
adhesion molecule 1 by hepatocellular carcinoma stem cells and
circulating tumor cells. Gastroenterology. 144:1031–1041. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Barclay AN and Brown MH: The SIRP family
of receptors and immune regulation. Nat Rev Immunol. 6:457–464.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Oldenborg PA, Gresham HD and Lindberg FP:
CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma
and complement receptor-mediated phagocytosis. J Exp Med.
193:855–862. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Okazawa H, Motegi S, Ohyama N, Ohnishi H,
Tomizawa T, Kaneko Y, Oldenborg PA, Ishikawa O and Matozaki T:
Negative regulation of phagocytosis in macrophages by the
CD47-SHPS-1 system. J Immunol. 174:2004–2011. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Blazar BR, Lindberg FP, Ingulli E,
Panoskaltsis-Mortari A, Oldenborg PA, Iizuka K, Yokoyama WM and
Taylor PA: CD47 (integrin-associated protein) engagement of
dendritic cell and macrophage counterreceptors is required to
prevent the clearance of donor lymphohematopoietic cells. J Exp
Med. 194:541–549. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Oldenborg PA, Zheleznyak A, Fang YF,
Lagenaur CF, Gresham HD and Lindberg FP: Role of CD47 as a marker
of self on red blood cells. Science. 288:2051–2054. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Majeti R, Chao MP, Alizadeh AA, Pang WW,
Jaiswal S, Gibbs KD Jr, van Rooijen N and Weissman IL: CD47 is an
adverse prognostic factor and therapeutic antibody target on human
acute myeloid leukemia stem cells. Cell. 138:286–299. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Chao MP, Jaiswal S, Weissman-Tsukamoto R,
Alizadeh AA, Gentles AJ, Volkmer J, Weiskopf K, Willingham SB,
Raveh T, Park CY, et al: Calreticulin is the dominant
pro-phagocytic signal on multiple human cancers and is
counterbalanced by CD47. Sci Transl Med. 2:63ra942010. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Willingham SB, Volkmer JP, Gentles AJ,
Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin
R, Cohen JD, et al: The CD47-signal regulatory protein alpha
(SIRPa) interaction is a therapeutic target for human solid tumors.
Proc Natl Acad Sci USA. 109:6662–6667. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Lee TK, Cheung VC, Lu P, Lau EY, Ma S,
Tang KH, Tong M, Lo J and Ng IO: Blockade of CD47-mediated
cathepsin S/protease-activated receptor 2 signaling provides a
therapeutic target for hepatocellular carcinoma. Hepatology.
60:179–191. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Lei ZJ, Wang J, Xiao HL, Guo Y, Wang T, Li
Q, Liu L, Luo X, Fan LL, Lin L, et al: Lysine-specific demethylase
1 promotes the stemness and chemoresistance of Lgr5+
liver cancer initiating cells by suppressing negative regulators of
β-catenin signaling. Oncogene. 34:32142015. View Article : Google Scholar : PubMed/NCBI
|
